Loading...
  • anemone
  • Four serine protease inhibitors (AEPI-I, II, III and IV) were isolated from the sea anemone Actinia equina by a slight modification of our previous method. (go.jp)
  • 2017
  • On May 17 th , 2017, Actinium Pharma announced that Dr. Richard Stone , Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School , has joined the Company's Scientific Advisory Board (SAB). (medindia.net)
  • bismuth-213
  • Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. (yahoo.com)
  • Significant research has been done in the separation of the alpha emitter Bismuth-213 from its parent solution of Actinium-225 using organic resins. (tennessee.edu)
  • Due to radiolytic damage to the resin emphasis in the research has focused on the rapid elution of Bismuth-213 or storage of the parent Actinium-225 solution on a more robust resin. (tennessee.edu)
  • If an inorganic resin could retain its structural integrity then Actinium-225 could be loaded on an inorganic resin bed with a clinical dose of Bismuth-213 eluted from the column when needed. (tennessee.edu)
  • The performance of two inorganic ion exchange resins, Isolute SCX and Isolute SCX-2, were compared to the performance of the organic resin AG-50X8 in the separation of the radionuclide Bismuth-213 from its parent solution of Actinium-225. (tennessee.edu)
  • Performance was based on the percent of Bismuth-213 available eluted, and the breakthrough of Actinium-225. (tennessee.edu)
  • Moore, Mark Alan, "The Separation of Bismuth-213 from Actinium-225 and the Ion Exchange Properties of the Alkali Metal Cations with an Inorganic Resin. (tennessee.edu)
  • Phase
  • With Iomab-B poised to enter a pivotal Phase 3 trial, Actimab-A moving towards a Phase 2 trial and an ever strengthening team it is an honor to join Actinium at such a momentous time for the Company. (marketwired.com)
  • Actinium previously announced positive interim data from the ongoing Phase 1/2 trial of Actimab-A in older patients with newly diagnosed AML. (marketwired.com)
  • CD33
  • Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies. (prnewswire.com)
  • joins
  • Mr. Zikaras joins Actinium from Bristol-Myers Squibb where he was a Clinical Protocol Manager in the Immuno-Oncology group since 2014. (equities.com)
  • Steve joins Actinium with almost a decade of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. (marketwired.com)
  • bone
  • SAB is comprised of independent physicians considered to be key opinion leaders in the field of hematology and bone marrow transplant that contribute to and advise Actinium on the development of Iomab-B, the Company's lead asset. (medindia.net)
  • Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. (actiniumpharma.com)
  • clinical
  • Actinium anticipates using the net proceeds for general corporate purposes, including capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs. (yahoo.com)
  • Actinium announced today the appointment of Rowena Choudrie, M.S. to the position of Senior Director, Pharmaceutical Product Development and Kevin Zikaras to the position of Senior Clinical Scientist. (equities.com)
  • At Actinium, Ms. Choudrie will be responsible for clinical trial material supply, drug product process scale-up to support commercial supply and final product formulation. (equities.com)
  • Dr. Mark S. Berger, MD, is Chief Medical Officer at Actinium Pharmaceuticals, Inc. Dr. Berger was previously employed as Vice President-Clinical Development by Gemin X Pharmaceuticals US, Inc., Group Director-Clinical Oncology by GlaxoSmithKline Plc, a Principal by University of Pennsylvania, and Senior Director-Oncology Clinical Development by Wyeth Pharmaceuticals, Inc. He received his undergraduate degree from Wesleyan University and a doctorate degree from the University of Virginia. (wsj.com)
  • In this role, Steve will initially focus on pre-commercial efforts including strategic planning and product messaging for Iomab-B, increasing awareness for Iomab-B, further developing relationships with the physician community, and supporting clinical trials for Actinium s current and future clinical programs. (salesandmarketingnetwork.com)
  • represents
  • This year's American Society of Hematology Annual Meeting represents a point of transformation for Actinium. (equities.com)
  • The positive results on both safety and anti-leukemic effect demonstrated in the completed third cohort represents a significant achievement for the Actimab-A program, and supports the advancement to a higher dose with the potential to further enhance the already strong results we have seen to date," stated Dragan Cicic, MD, Chief Medical Officer of Actinium. (marketwired.com)
  • patients
  • Actinium had previously reported a 56% response rate in patients that were evaluable at time of the abstract submission when data were available on 9 patients compared to the 13 patients reported in the poster. (globenewswire.com)
  • I look forward to working with Steve and the rest of the Actinium team in building a great company that is focused on improving outcomes for patients. (salesandmarketingnetwork.com)